How is terbinafine indicated, dosed, and monitored for treatment of dermatophyte infections, and what are its contraindications and alternatives?

Terbinafine for Dermatophyte Infections

Terbinafine is the first-line oral treatment for dermatophyte onychomycosis and Trichophyton species infections, dosed at 250 mg daily for 6 weeks (fingernails) or 12-16 weeks (toenails), with mandatory baseline liver function tests and complete blood count before initiation. 1, 2

Indications

Terbinafine is indicated for:

• Onychomycosis (nail infections) caused by dermatophytes 2
• Trichophyton species infections (T. tonsurans, T. violaceum, T. soudanense, T. rubrum, T. mentagrophytes) - highly effective 3, 1
• Tinea capitis, pedis, corporis/cruris when systemic therapy is warranted 3

Critical caveat: Terbinafine is significantly less effective against Microsporum species (particularly M. canis), where griseofulvin is preferred. This is because terbinafine cannot be incorporated into hair shafts in prepubertal children and doesn't reach scalp surface arthroconidia effectively 3.

Dosing Regimens

Adults

• Fingernail onychomycosis: 250 mg once daily for 6 weeks 1, 2
• Toenail onychomycosis: 250 mg once daily for 12-16 weeks 1, 2
• Re-evaluate 3-6 months after treatment completion; optimal clinical effect occurs months after mycological cure due to healthy nail outgrowth 1, 2

Children (weight-based dosing for onychomycosis)

• <20 kg: 62.5 mg daily 1
• 20-40 kg: 125 mg daily 1
• >40 kg: 250 mg daily 1
• Duration: 6 weeks for fingernails, 12 weeks for toenails 1

Note: Terbinafine is unlicensed for pediatric onychomycosis but is recommended as first-line with appropriate monitoring 1.

Monitoring Requirements

Baseline (Mandatory)

• Liver function tests (LFTs) 1, 2
• Complete blood count (CBC) 1, 2

Additional baseline monitoring required for:

• Heavy alcohol consumption 1
• History of hepatitis or liver disease 1
• Hematological abnormalities 1
• All pediatric patients (due to unlicensed use) 1

During Treatment

Monitor LFTs if:

• Continuous therapy exceeds 1 month 1
• Concomitant hepatotoxic drug use 1
• Pre-existing abnormal LFTs 1

Discontinue immediately if: Persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools, or elevated LFTs develop 2.

Contraindications

Absolute Contraindications

• Active or chronic liver disease 1, 2
• History of allergic reaction to oral terbinafine (anaphylaxis risk) 2
• Lupus erythematosus 3
• Porphyria 3

Relative Contraindications

• Severe renal impairment (clearance decreased) 1
• Pregnancy 2

Common Adverse Effects

From postmarketing surveillance 1:

• Gastrointestinal (49%): nausea, diarrhea, dyspepsia, abdominal pain 1, 2
• Dermatological (23%): rash, pruritus, urticaria, eczema 1
• Taste disturbance (including loss): Can be severe, prolonged (>1 year), or permanent - warn patients and discontinue if occurs 1, 2
• Smell disturbance (including loss): May be prolonged or permanent - discontinue if occurs 2
• Headache 1, 2

Serious Adverse Events (Rare, 0.04%)

• Hepatotoxicity leading to liver failure, transplant, or death 1, 2
• Stevens-Johnson syndrome, toxic epidermal necrolysis 1, 2
• Severe neutropenia (discontinue if ≤1,000 cells/mm³) 2
• DRESS syndrome 2
• Depressive symptoms 2
• Can aggravate psoriasis or cause subacute lupus-like syndrome 1

Drug Interactions

Terbinafine has minimal drug interactions compared to azoles 1, 4. Key interactions:

• CYP2D6 substrates: Terbinafine inhibits this enzyme 2
• Rifampin: Decreases terbinafine plasma concentration 3
• Cimetidine: Increases terbinafine plasma concentration 3

Efficacy and Alternatives

Superiority Over Other Agents

Terbinafine is superior to itraconazole for dermatophyte onychomycosis 1:

• Complete cure: 55% vs 26% (terbinafine vs itraconazole pulse therapy) 1
• 5-year mycological cure without re-treatment: 46% vs 13% 1
• Relapse rates significantly lower: 23% vs 53% 1

Terbinafine is also more effective than griseofulvin and fluconazole for dermatophyte infections 1, 4, 5.

Alternative Treatments (in order of preference)

When terbinafine is contraindicated or ineffective:

1. Itraconazole (second-line for dermatophytes) 1

   • Pulse therapy: 400 mg daily for 1 week/month
   • 2 pulses for fingernails, 3 pulses for toenails
   • Better for Candida species 1

2. Fluconazole (third-line) 1

   • 150-450 mg weekly for 3 months (fingernails) or ≥6 months (toenails)
   • Requires dose adjustment for renal impairment 1

3. Griseofulvin (fourth-line, mainly for Microsporum or pediatric use) 3, 1

   • Adults: 500-1000 mg daily for 6-9 months (fingernails) or 12-18 months (toenails)
   • Children: 10 mg/kg daily (licensed for pediatric onychomycosis) 1
   • Take with fatty food for absorption 1
   • Preferred over terbinafine for Microsporum infections 3

Emerging Resistance Concerns

Critical emerging issue: Terbinafine resistance is increasing globally, particularly in Trichophyton species 6, 7, 8, 9:

• Resistance increased from 0.63% (2013) to 1.3% (2021) 9
• Associated with SQLE gene mutations (F397L, L393F, A448T most common) 7, 9
• T. indotineae is a newly described resistant species causing widespread, treatment-refractory infections 8
• Proposed MIC breakpoint for resistance: ≥0.015 μg/mL (though no standardized breakpoints exist) 7, 9

If treatment failure occurs: Consider antifungal susceptibility testing and SQLE genotyping where available 7, 9.

Key Clinical Pitfalls

1. Don't use terbinafine for Microsporum infections - use griseofulvin instead 3
2. Always obtain baseline LFTs and CBC - hepatotoxicity can occur even without pre-existing disease 1, 2
3. Warn patients about permanent taste/smell loss - this is not reversible in all cases 2
4. Confirm diagnosis mycologically before treatment (KOH, culture, or nail biopsy) 2
5. Don't expect immediate clinical improvement - healthy nail outgrowth takes months after mycological cure 1, 2
6. Monitor for depressive symptoms during treatment 2